Patent US4503070A successfully refreshed from Google Patents.
US4503070A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for reducing the duration of the common cold
Assignee: Individual
•
Filing: 1982-05-14
•
Granted: 1985-03-05
•
Expires: 2002-05-14
Abstract
Abstract The invention disclosed and claimed is a method to reduce duration of common colds in humans as evinced by reduction of duration of 10 common cold symptoms through use of zinc gluconate topically and frequently applied to the oral mucosa. The invention improves upon the prior art using zinc intranasally as an astringent and decongestant in treatment of common colds. Results of a clinical study are presented in support of disclosure and claims.
Inventors
- 👤 George A. Eby, III
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 19:46
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/28; A61K31/315
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
96 words
The method of administering an agent to reduce duration of common cold symptoms in humans, which includes reducing the duration of nasal drainage, nasal congestion, headache, fever, myalgia, sneeezing, sore throat, scratchy throat, cough, and horseness when such symptoms evince existence of a common cold, comprising: applying, in the form of a lozenge, zinc gluconate to the oral mucosa of a human in need of treatment; permitting zinc to remain in contact with the mucosa for a period of time necessary for lozenges to dissolve; and applying additional dosages of zinc until the symptoms have disappeared.
Claim 2
Independent Claim
96 words
The method of administering an agent to reduce duration of common cold symptoms in humans, which includes reducing the duration of nasal drainage, nasal congestion, headache, fever, myalgia, sneeezing, sore throat, scratchy throat, cough, and horseness when such symptoms evince existence of a common cold, comprising: applying, in the form of a lozenge, zinc gluconate to the oral mucosa of a human in need of treatment; permitting zinc to remain in contact with the mucosa for a period of time necessary for lozenges to dissolve; and applying additional dosages of zinc until the symptoms have disappeared.
Claim 3
Dependent Claim
19 words
The method according to claim 1 wherein dosages of zinc gluconate each contain 2 to 50 milligrams of zinc.
Claim 4
Dependent Claim
51 words
The method according to claim 1 wherein the first dosage of zinc gluconate is double that of additional dosages, additional dosages each consists of a single lozenge given two hours after a previously applied dosage, and all dosages are applied during the waking hours of the human in need of treatment.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-03-04 | 1988-09-03 | 1989-03-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-03-04 | 1992-09-03 | 1993-03-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-03-04 | 1996-09-03 | 1997-03-05 | $7700.00 | Window Closed / Lapsed |